{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058154","form_type":"8-K","ticker":"CERS","cik":"0001020214","company_name":"CERUS CORP","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.899883+00:00","generated_at":"2026-06-08T23:04:54.665043+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CERS Q3 product revenue $39.8M, net loss $7.3M; FY product revenue guidance cut to $155-158M","bullets":["Total Q3 revenue $47.3M ($39.8M product, $7.5M govt); net loss $7.3M ($0.04/share) vs $8.5M loss year ago.","Non-GAAP adjusted EBITDA -$1.0M, improved from -$2.7M; reaffirms Q4 2023 breakeven target.","Full-year 2023 product revenue guidance revised to $155-158M, citing delay in signing IFC sales agreement.","Completed Phase 3 ReCePI study enrollment; top-line data expected Q1 2024.","Cash and investments $79M at Sep 30, down from $102.2M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058154","json":"https://secwatch.observer/filing/0000950170-23-058154.json","markdown":"https://secwatch.observer/filing/0000950170-23-058154.md","text":"https://secwatch.observer/filing/0000950170-23-058154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1020214/000095017023058154/0000950170-23-058154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1020214/000095017023058154/cers-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:04:54.665043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ec704cb4aef4ab816a225bbe89fb3be5d333eba","claim":"CERUS CORP reported third quarter ended September 30, 2023 results: revenue $47.3 million, net income $7.3 million, EPS $0.04 per basic and diluted share. Guidance lowered.","evidence_excerpt":"Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: • Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million and government contract revenue of $7.5 million. • Completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients, with top-line data readout on track for Q1 2024. • Attended first in-person AABB Annual Meeting since 2019, where presentations from transfusion medicine leaders highlighted the growing experience with the benefits of INTERCEPT-treated products, including INTERCEPT platelets and INTERCEPT Fibrinogen Complex (IFC). • Cash, cash equivalents, and short-term investments were $79.0 million at September 30, 2023. • Reaffirming commitment to achieve non-GAAP adjusted EBITDA breakeven in the fourth quarter of 2023. “We continued to make progress on multiple fronts in the third quarter,” said William “Obi” Greenman, Cerus’","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1020214/000095017023058154/0000950170-23-058154-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$47.3 million"},{"label":"Net income","value":"$7.3 million"},{"label":"EPS","value":"$0.04 per basic and diluted share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}